Company profile: PharmaFluidics

1.1 - Company Overview

PharmaFluidics

Headquarter: Belgium

Founded: 20XX🔒

Employees: 100-500🔒

🌐 Website

Company description

Provider of integrated milli- to nano-engineered solutions for mixing, separation and reaction processes, offering high-quality, tailor-made designs. Products include Î¼PAC Neo silicon-based HPLC columns for high-resolution separations; EASY-Spray and Double nanoViper columns for nano/capillary LC-MS and robust proteomics; MAbPac RP for intact protein characterization; Accucore 150 Amide HILIC for hydrophilic biomolecules/glycans.

Products and services

Double nanoViper HPLC Columns: Constructs robust separation components with double nanoViper fingertight fittings for dependable proteomics research and consistent throughput in high‑volume laboratories
EASY-Spray HPLC Columns: Delivers simple connections and high sensitivity for nano-scale and capillary LC‑MS analysis, architected for proteomics plus targeted and untargeted screening applications
μPAC Neo HPLC Columns: Silicon-based, engineered for high-resolution separations, delivering excellent reproducibility and peak capacity across a wide range of flow rates and sample amounts.

Key contacts

🔒

Financial details

🔒

1.2 - Competitors and similar companies to PharmaFluidics

Echelon Biosciences

HQ: United States Website

Description: Provider of tools and reagents for biomedical research and drug discovery, including Membrane Lipid Strips for protein-lipid interaction assays; PIP3 Mass ELISA for PI(3,4,5)P3 detection; lipid antibodies; Hyaluronidase Activity ELISA; neuroscience resources for nervous system studies; and cell membrane resources for lipid-protein interactions and membrane analysis.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Echelon Biosciences company profile →

Abcam

HQ: United Kingdom Website

Description: Provider of antibodies, proteins, and kits and reagents for life science research, validated for research use to support scientific studies and facilitate experimental procedures. Helps researchers with breakthroughs in cancer, neurological disorders, infectious diseases, and metabolic disorders.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Abcam company profile →

Crawford Scientific

HQ: United Kingdom Website

Description: Provider of chromatography consumables and products (columns, vials, syringe filters, gas generators), analytical services, and chromatography/mass spectrometry training, offering HPLC columns, technical support and consultancy, online training courses, and the CHROMacademy eLearning platform.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Crawford Scientific company profile →

AxioMx

HQ: United States Website

Description: Provider of antibody discovery and development services for the research and diagnostics marketplace, leveraging recombinant antibody technologies.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full AxioMx company profile →

Nortis Bio

HQ: United States Website

Description: Provider of organ-on-a-chip systems and tissue-engineering techniques that create human micro-tissue environments within small, disposable microfluidic chips, enabling living models of human organs to accelerate discovery and help scientists better understand the causes of human diseases.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Nortis Bio company profile →

🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒

🔒 View all strategic buyers with complete profiles

Start Free Trial →

2.2 - Strategic buyer groups for PharmaFluidics

🔒

Buyer group 1: ████████ ████████

●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔒

Buyer group 2: ████████ ████████

●● companies

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔒

Buyer group 3: ████████ ████████

●● companies

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔓 Unlock all detailed buyer group breakdowns with complete company profiles

Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to PharmaFluidics

Buyout Funds
50+ funds

🔒

🔒

🔒

🔒

🔒 🇺🇸 Top US buyout funds investing in PharmaFluidics's sector and industry vertical
View Funds →
🔒 🇪🇺 Top Europe buyout funds in PharmaFluidics's sector and industry vertical
View Funds →

2.2 - Growth funds investing in similar companies to PharmaFluidics

Growth Equity Funds
40+ funds

🔒

🔒

🔒

🔒

🔒 🇺🇸 Top US growth equity funds investing in PharmaFluidics's sector and industry vertical
View Funds →
🔒 🇪🇺 Top Europe growth equity funds investing in PharmaFluidics's sector and industry vertical
View Funds →

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for PharmaFluidics

4.2 - Public trading comparable groups for PharmaFluidics

🔒

Comparable group 1: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔒

Comparable group 2: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔒

Comparable group 3: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to PharmaFluidics

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA

🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About PharmaFluidics

What does PharmaFluidics do?

PharmaFluidics is a provider of integrated milli- to nano-engineered solutions for mixing, separation and reaction processes, offering high-quality, tailor-made designs. Products include Î¼PAC Neo silicon-based HPLC columns for high-resolution separations; EASY-Spray and Double nanoViper columns for nano/capillary LC-MS and robust proteomics; MAbPac RP for intact protein characterization; Accucore 150 Amide HILIC for hydrophilic biomolecules/glycans.

Who are PharmaFluidics's competitors?

PharmaFluidics's competitors and similar companies include Echelon Biosciences, Abcam, Crawford Scientific, AxioMx, and Nortis Bio.

Where is PharmaFluidics headquartered?

PharmaFluidics is headquartered in Belgium.

How many employees does PharmaFluidics have?

PharmaFluidics has 1,000 employees 🔒.

When was PharmaFluidics founded?

PharmaFluidics was founded in 2010 🔒.

What sector and industry vertical is PharmaFluidics in?

PharmaFluidics is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for PharmaFluidics

Who are the top strategic acquirers in PharmaFluidics's sector and industry

Top strategic M&A buyers and acquirers in PharmaFluidics's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for PharmaFluidics?

Top strategic M&A buyers groups and sectors for PharmaFluidics include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in PharmaFluidics's sector and industry vertical

Which are the top PE firms investing in PharmaFluidics's sector and industry vertical?

Top PE firms investing in PharmaFluidics's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in PharmaFluidics's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in PharmaFluidics's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in PharmaFluidics's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to PharmaFluidics include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in PharmaFluidics's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for PharmaFluidics?

The key public trading comparables and valuation benchmarks for PharmaFluidics include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for PharmaFluidics for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for PharmaFluidics with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in PharmaFluidics's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for PharmaFluidics with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in PharmaFluidics's' sector and industry vertical?

Access recent funding rounds and capital raises in PharmaFluidics's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for PharmaFluidics

Start Free Trial Book a Demo